SCHEMBL23535713

SCHEMBL23535713

C=C(c1ccc(C(=O)OC)cc1)c1ccccn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.67
▸ KDM4E B2RXH2 5/20 0.67
▸ POLB P06746 1/20 0.67
▸ PKM P14618 5/20 0.62
▸ RAB9A P51151 9/20 0.56
▸ NPC1 O15118 7/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ NFKB1 P19838 1/20 0.56
▸ NFKB2 Q00653 1/20 0.56
▸ RELA Q04206 1/20 0.56
▸ CDK5 Q00535 4/20 0.50
▸ CDK5R1 Q15078 4/20 0.50
▸ PAX8 Q06710 3/20 0.50
▸ HPGD P15428 2/20 0.50
▸ TSHR P16473 1/20 0.50
▸ KMT2A Q03164 1/20 0.48
▸ RGS12 O14924 1/20 0.47
▸ CASP3 P42574 2/20 0.47
▸ SENP8 Q96LD8 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30039573 1.00 MAPT (0.67) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL9336728 0.87 KDM4E (0.55) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL13600088 0.84 MAPT (0.70) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL29289270 0.81 RAB9A (0.60) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL4311315 0.80 SMN1; SMN2 (0.71) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL4317855 0.80 MAPT (0.65) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL4317861 0.80 MAPT (0.65) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL27665086 0.80 MAPT (1.00) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL4317866 0.80 MAPT (0.65) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL30166417 0.79 KDM4E (0.68) MAPTKDM4EPOLBPKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 — — US disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 — — US disclosed
CN-115427035-A ENL/AF9YEATS inhibitors 洛克菲勒大学 2022-12-02 — — CN disclosed
EP-4076440-A1 INHIBITORS OF ENL/AF9 YEATS The Rockefeller University (US) 2022-10-26 — — EP disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 — — WO disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS MLLT3, YEATS2, MLLT1 MAPT 3429/4885KDM4E 84/4885POLB 4736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback